3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
4
Thoracic
1
Sarcoma
1
Head & Neck
1
Conditions
Head and Neck Neoplasms
26
Squamous Cell Carcinoma of Head and Neck
25
Salivary Gland Neoplasms
8
Carcinoma, Non-Small-Cell Lung
6
Tongue Neoplasms
5
Rectal Neoplasms
3
Pancreatic Neoplasms
3
Esthesioneuroblastoma, Olfactory
3
Colonic Neoplasms
3
Carcinoma, Squamous Cell
3
Pharyngeal Neoplasms
2
Mouth Neoplasms
2
Laryngeal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Carcinoma, Hepatocellular
2
Anus Neoplasms
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Tonsillar Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Parotid Neoplasms
1
Paranasal Sinus Neoplasms
1
Oropharyngeal Neoplasms
1
Oligodendroglioma
1
Neuroectodermal Tumors, Primitive
1
Interventions
pembrolizumab
31
Nivolumab
11
Ipilimumab
6
spartalizumab
5
cemiplimab
5
atezolizumab
5
Gemcitabine
4
Docetaxel
4
durvalumab
3
budigalimab
3
avelumab
3
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Immune Checkpoint Inhibitors
3
Fluorouracil
3
Cyclophosphamide
3
Cetuximab
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
obinutuzumab
2
lenvatinib
2
fludarabine
2
epacadostat
2
X-Rays
2
Paclitaxel
2
Immunoglobulin G
2
Cisplatin
2
Capecitabine
2
Biopsy
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
Erlotinib Hydrochloride
×
Head & Neck
×
Clear all
NCT05827614
2026-01-23
POTENTIATE
Boundless Bio, Inc.
Phase 1
Active not recruiting
85 enrolled